140 related articles for article (PubMed ID: 35523402)
1. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer.
Li N; Geng F; Liang SM; Qin X
Cell Signal; 2022 Aug; 96():110351. PubMed ID: 35523402
[TBL] [Abstract][Full Text] [Related]
2. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract][Full Text] [Related]
4. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
5. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
[TBL] [Abstract][Full Text] [Related]
6. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
Li B; Wang B
Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
[TBL] [Abstract][Full Text] [Related]
7. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway.
Zeng J; He SL; Li LJ; Wang C
Mol Med; 2021 Oct; 27(1):130. PubMed ID: 34666670
[TBL] [Abstract][Full Text] [Related]
9. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
10. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
11. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
Theranostics; ; . PubMed ID: 32802195
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
